WebbA., CunninghamD., ScarffeJ.H.Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.J Clin Oncol15: 261–267, 1997.
3.
CascinuS., LabiancaR., GrazianoF., PanceraG., BarniS., FrontiniL., LeporiniG., CellerinoR., CatalanoG.Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, gluthatione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).Br J Cancer78: 390–393, 1998.
SulkesA., SmythJ., SessaC., DirixL.Y., VermorkenJ.B., KayeS., WandersJ., FranklinH., Le BailN., VerweijJ.Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial.Br J Cancer70: 380–383, 1994.
6.
TaguchiT.A late phase II study of docetaxel in patients with gastric cancer.Proc ASCO15: 934 (abstr) 1997.
7.
EinzigA.I., NeubergD., RemickS.C., KarpD.D., O'DwyerP.J., StewardJ.A., BensonA.B.Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.Med Oncol, 13: 87–93, 1996.
8.
VanhoeferU., WilkeH., HarstrickA., AchterrathW., PreusserP., StahlM., ClemensM.R., ThielE., FlasshoveM., FinkU., TrennG., SeeberS.Phase II study of docetaxel as second line chemotherapy in metastatic gastric cancer.Proc ASCO18: 1163 (abst), 1999.
9.
MavroudisD., KourousisC., AndroulakisN., KalbakisK., AgelakiS., KakolyrisS., SouglakosJ., SarraE., VardakisN., HatzidakiD., SarmonisG., GeorgouliasV.Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.Am J Clin Oncol, 23: 341–344, 2000.
10.
CascinuS., GrazianoF., BarniS., LabiancaR., CorneliaG., CasarettiR., FrontiniL., CatalanoV., BaldelliA.M., CatalanoG.A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian Group for the digestive tract cancer.Br J Cancer84: 470–474, 2000.
11.
RothA.D., MaibachR., MartinelliG., FazioN., AaproM.S., PaganiO., MorantR., BornerM.M., HerrmannR., HonneggerH., CavalliF., AlbertoP., CastiglioneM., GoldhirschA.Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).Ann Oncol11: 301–306, 2000.
12.
RidwelskiK., GebauerT., FahlkeJ., KroningH., KettnerE., MeyerF., EichelmannK., LippertH.Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer.Ann Oncol12: 47–51, 2001.
13.
RothA.D., MaibachR., FazioN., PaganiO., MorantR., StuppP., De BraudF., SessaC., BornerM.M., HerrmannR., GoldhirischA.5FU as protracted continuous iv infusion can be added to full dose taxotere-cisplatin in advanced gastric carcinoma.Eur J Cancer35(suppl 4): 139, 1999.
14.
Van CutsernE., AyaniJ., TjulandinS., MoiseyenkoV., CabralF., MajllA., ZuberE., BlattmannA., GarayC., JacquesC.Docetaxel in combination with cisplatinum with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma: preliminary results.Ann Oncol11(suppl 4): 276, 2000.
